GlassScriptPhysician profile
Kenneth Stephen Roca
NPI 1912600503
$1,174.67
in general payments reported to CMS, 2019-2025
15 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $225 · 2024: $301 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $273.07 | 2024-2025 | |
| Shionogi INC | $125.01 | 2025 | Fetroja |
| Pfizer INC. | $125.00 | 2025 | |
| La Jolla Pharmaceutical Company | $124.99 | 2025 | Zevtera |
| Medtronic, INC. | $124.52 | 2023 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $82.78 | 2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $71.53 | 2023-2024 | Airsupra, Farxiga |
| Boston Scientific Corporation | $57.34 | 2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.41 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $33.03 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $25.44 | 2024 | Capvaxive |
| Purdue Pharma L.P. | $23.08 | 2024 | Nalmefene Hydrochloride |
| Lilly USA, LLC | $22.30 | 2025 | Zepbound |
| Novo Nordisk INC | $22.06 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.11 | 2025 | Xhance, Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Roca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.